

NSCLC blood-based liquid biopsy test

January 2015—Biocept launched its lung cancer liquid biopsy testing, performed at its CLIA-certified, CAP-accredited laboratory. The blood-based biomarker testing for non-small cell lung cancer, along with the previously commercialized breast cancer offering, provides options for health care professionals and researchers for when a tumor biopsy is not available or is unsafe to perform or when additional information is desired. Biocept's first CLIA-validated assay for lung cancer will be testing for ALK fusions on circulating tumor cells captured in the company's patented device.

Additional biomarkers for lung cancer will be offered in the year ahead, including for EGFR mutations, ROS1 fusions, KRAS mutations, and EGFR and MET amplification. In addition, the company is validating important resistance markers for targeted therapies that are used when monitoring patients.

[**Biocept**](#), 858-320-8200